CD8A and neoplasm: Consequently, administration of a CXCR4 inhibitor during the circadian phase of elevated CXCR4 expression in tumor‐infiltrated CD8+ T cells promotes their dispersion throughout tumor tissues, thereby enhancing the efficacy of ICIs.